Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Deferred Tax Assets (2016)

Historic Current Deferred Tax Assets for Enanta Pharmaceuticals (ENTA) over the last 3 years, with Q2 2016 value amounting to $1.1 million.

  • Enanta Pharmaceuticals' Current Deferred Tax Assets fell 3471.83% to $1.1 million in Q2 2016 from the same period last year, while for Jun 2016 it was $1.1 million, marking a year-over-year decrease of 3471.83%. This contributed to the annual value of $1.4 million for FY2015, which is 8699.09% down from last year.
  • According to the latest figures from Q2 2016, Enanta Pharmaceuticals' Current Deferred Tax Assets is $1.1 million, which was down 3471.83% from $1.6 million recorded in Q1 2016.
  • Enanta Pharmaceuticals' Current Deferred Tax Assets' 5-year high stood at $11.2 million during Q2 2014, with a 5-year trough of $1.1 million in Q2 2016.
  • Moreover, its 3-year median value for Current Deferred Tax Assets was $1.6 million (2015), whereas its average is $3.6 million.
  • The largest annual percentage gain for Enanta Pharmaceuticals' Current Deferred Tax Assets in the last 5 years was 1728.49% (2015), contrasted with its biggest fall of 8699.09% (2015).
  • Quarter analysis of 3 years shows Enanta Pharmaceuticals' Current Deferred Tax Assets stood at $1.3 million in 2014, then grew by 17.28% to $1.6 million in 2015, then dropped by 27.45% to $1.1 million in 2016.
  • Its last three reported values are $1.1 million in Q2 2016, $1.6 million for Q1 2016, and $1.6 million during Q4 2015.